Back to top

ICAGEN ANNOUNCES SECOND RENEWAL OF PFIZER COLLABORATION

Collaboration Agreement

ICAGEN ANNOUNCES SECOND RENEWAL OF PFIZER COLLABORATION | Document Parties: ICAGEN INC | Icagen, Inc You are currently viewing:
This Collaboration Agreement involves

ICAGEN INC | Icagen, Inc

. RealDealDocs™ contains millions of easily searchable legal documents and clauses from top law firms. Search for free - click here.
Title: ICAGEN ANNOUNCES SECOND RENEWAL OF PFIZER COLLABORATION
Date: 9/27/2010
Industry: Biotechnology and Drugs     Sector: Healthcare

50 of the Top 250 law firms use our Products every day

Exhibit 99.1

Contacts :

Richard D. Katz, M.D.

EVP, Finance and Corporate Development;

Chief Financial Officer

Icagen, Inc.

(919) 941-5206

rkatz@icagen.com

ICAGEN ANNOUNCES SECOND

RENEWAL OF PFIZER COLLABORATION

RESEARCH TRIANGLE PARK, NC, September 23, 2010 – Icagen, Inc. (NASDAQ: ICGND) today announced an additional extension through December 2011 to an existing worldwide collaboration and licensing agreement with Pfizer aimed at discovering, developing and commercializing compounds that modify three specific sodium ion channels as new potential treatments for pain and related disorders.

For the past three years, Icagen and Pfizer have partnered to identify compounds that target three specific sodium ion channels in a global research and development collaboration overseen by a joint research committee. These sodium channels are important in the generation of electrical signals in nerve fibers that mediate the initiation, transmission and sensation of pain. By selectively targeting these ion channels, the companies seek to develop effective treatments for serious pain disorders.

During the extension period, Pfizer will continue to fund all aspects of the collaboration including research efforts at both companies and all clinical development costs. Pfizer also will continue to have exclusive worldwide rights to commercialize products resulting from the collaboration. Under the terms of the extended agreement, Pfizer will provide approximately $5 million in committed funding to Icagen through December 2011. Additionally, Icagen remains eligible to receive approximately $359 million upon achievement of specified research, development, regulatory and commercialization milestones for each product. Icagen is also eligible to receive tiered royalties, against which the commercialization milestones are creditable, based upon product sales.

“We are very pleased to announce this extension of our collaboration with Pfizer,” noted P. Kay Wagoner, Ph.D., President and CEO of Icagen. “The collaboration has made substantial progress, as highlighted by the recent initiation of clinical studies with compounds directed against Nav1.7. In addition, we continue to make progress in identifying additional compounds targeting the sodium channels that form the basis for the collaboration. Pfizer has


SITE SEARCH

AGREEMENTS / CONTRACTS

Document Title:

Entire Document: (optional)

Governing Law:(optional)
 

CLAUSES

Search Contract Clauses >>

Browse Contract Clause Library>>

Close this window